An imidazopyridine anxiolytic alters glucose tolerance in patients: a pilot investigation.
We have recently shown that compounds with high affinity for peripheral-type benzodiazepine receptors inhibited glucose-induced insulin secretion in vitro. We therefore performed an oral glucose tolerance test in anxious inpatients treated with the imidazopyridine derivative alpidem, which has been shown to display high affinity for these binding sites. The test was performed before and after 1 week of daily administration of the drug. As compared with pretreatment values, a significant alteration of the insulin response to glucose was observed. It is suggested that daily administration of alpidem, at therapeutically effective doses for the treatment of anxiety, may alter glucose tolerance.
Bottaï
T
T
Unité de Psychopharmacologie, CHU Hôpital de La Colombière, France.
Cartault
F
F
Pouget
R
R
Blayac
J P
JP
Petit
P
P
D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy*; D001786:Blood Glucose / Q000187:drug effects*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood*; D011725:Pyridines / Q000627:therapeutic use*; D013997:Time Factors
D014151:Anti-Anxiety Agents; D001786:Blood Glucose; D007093:Imidazoles; D007328:Insulin; D011725:Pyridines; C052036:alpidem